<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioporto — News on 6ix</title>
<link>https://6ix.com/company/bioporto</link>
<description>Latest news and press releases for Bioporto on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 08:49:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioporto" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836223478dffbe2df141ed7.webp</url>
<title>Bioporto</title>
<link>https://6ix.com/company/bioporto</link>
</image>
<item>
<title>Major Shareholder Announcement</title>
<link>https://6ix.com/company/bioporto/news/major-shareholder-announcement-10</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/major-shareholder-announcement-10</guid>
<pubDate>Mon, 13 Apr 2026 08:49:00 GMT</pubDate>
<description>April 13, 2026 Company Announcement No. 8 Major Shareholder Announcement COPENHAGEN, DENMARK and BOSTON, MA, USA, 13 April 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) hereby announces, pursuant to sections 30 and 38 of the Danish Capital Markets Act, that the Company has received a major shareholder notification from Martin Bundgaard. As of 8 April 2026, Martin Bundgaard has exceeded the 5% threshold of the total share capital and voting rights in BioPorto A/S. As of 8 April</description>
</item>
<item>
<title>BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC</title>
<link>https://6ix.com/company/bioporto/news/bioporto-successfully-completes-divestment-of-its-antibody-business-to-janel-life-sciences-llc-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-successfully-completes-divestment-of-its-antibody-business-to-janel-life-sciences-llc-1</guid>
<pubDate>Wed, 08 Apr 2026 13:16:00 GMT</pubDate>
<description>April 8, 2026 Company Announcement No. 7 BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) today announces the successful signing and simultaneous closing of an agreement to divest its antibody business to Janel Life Sciences LLC, a subsidiary of the Janel Corporation. The transaction encompasses BioPorto’s antibody business and represent</description>
</item>
<item>
<title>BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis</title>
<link>https://6ix.com/company/bioporto/news/bioporto-advances-us-adult-urine-ngal-program-with-fda-pre-submission-request-after-positive-epacra-aki-cut-off-analysis-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-advances-us-adult-urine-ngal-program-with-fda-pre-submission-request-after-positive-epacra-aki-cut-off-analysis-1</guid>
<pubDate>Tue, 31 Mar 2026 15:43:00 GMT</pubDate>
<description>March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary analysis recently completed fo</description>
</item>
<item>
<title>BioPorto announces the Annual Report for 2025</title>
<link>https://6ix.com/company/bioporto/news/bioporto-announces-the-annual-report-for-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-announces-the-annual-report-for-2025-1</guid>
<pubDate>Thu, 26 Mar 2026 06:43:00 GMT</pubDate>
<description>March 26, 2026Announcement no. 04 BioPorto announces the Annual Report for 2025 Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or company) (CPH:BIOPOR), today announced the annual financial results for 2025. The financial results for 2025 confirm the preliminary unaudited 2025 financial figures released February 5, 2026. Financial highlights for FY 2025 Total revenues amounted to DKK 40.3 million – an 11% growth compared to 2024 and 13% growth at</description>
</item>
<item>
<title>BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026</title>
<link>https://6ix.com/company/bioporto/news/bioporto-successfully-completes-preliminary-analysis-of-us-adult-ngal-cutoff-study-pre-submission-expected-by-end-of-q1-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-successfully-completes-preliminary-analysis-of-us-adult-ngal-cutoff-study-pre-submission-expected-by-end-of-q1-2026-1</guid>
<pubDate>Wed, 18 Mar 2026 17:55:00 GMT</pubDate>
<description>March 18, 2026Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of NGAL in assessing risk of acute kidney injury (AKI). The Company intends to submit i</description>
</item>
<item>
<title>BioPorto A/S Appoints Chief Financial Officer</title>
<link>https://6ix.com/company/bioporto/news/bioporto-appoints-chief-financial-officer-071200342</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-appoints-chief-financial-officer-071200342</guid>
<pubDate>Mon, 09 Feb 2026 07:12:00 GMT</pubDate>
<description>February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he ser</description>
</item>
<item>
<title>BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update</title>
<link>https://6ix.com/company/bioporto/news/bioporto-provides-preliminary-unaudited-2025-200100350</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-provides-preliminary-unaudited-2025-200100350</guid>
<pubDate>Thu, 05 Feb 2026 20:01:00 GMT</pubDate>
<description>February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update. A strong quarter to close out the year - Preliminary Financial Figures for the Fourth Quarter of 2025 and Fiscal Y</description>
</item>
<item>
<title>Changes to the Executive Management</title>
<link>https://6ix.com/company/bioporto/news/changes-executive-management-163100259</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/changes-executive-management-163100259</guid>
<pubDate>Thu, 11 Dec 2025 16:31:00 GMT</pubDate>
<description>December 11, 2025 Announcement no. 29 Changes to the Executive Management COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto”) (CPH:BIOPOR) announced today that Niels Høy Nielsen has resigned as CFO of BioPorto to become CFO at another company. “I have valued the close collaboration with Niels during the last couple of months since I joined BioPorto. He has made important contributions across the company and wish him all the best in his future e</description>
</item>
<item>
<title>Managers’ transactions</title>
<link>https://6ix.com/company/bioporto/news/managers-transactions-093800194</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/managers-transactions-093800194</guid>
<pubDate>Mon, 24 Nov 2025 09:38:00 GMT</pubDate>
<description>November 24, 2025Announcement no. 28 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 27, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsibil</description>
</item>
<item>
<title>BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes</title>
<link>https://6ix.com/company/bioporto/news/bioporto-raises-approximately-dkk-43-090900143</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-raises-approximately-dkk-43-090900143</guid>
<pubDate>Mon, 24 Nov 2025 09:09:00 GMT</pubDate>
<description>24 November 2025 Announcement no. 27 BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, 24 November 2025 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), decided on 13 November 2025, to complete a private placement of 40,438,426 new shares to existing larger shareholders, new institutional and private investors, and to board memb</description>
</item>
<item>
<title>BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth</title>
<link>https://6ix.com/company/bioporto/news/bioporto-interim-result-third-quarter-063200718</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-interim-result-third-quarter-063200718</guid>
<pubDate>Wed, 19 Nov 2025 06:32:00 GMT</pubDate>
<description>November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth. Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the third quarter of 2025, unchanged from the pre-announced Key Financial Results that were announced on November 4, 2025. Highlights of key strategic milestones and a renewed strategy, “Forwa</description>
</item>
<item>
<title>Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S</title>
<link>https://6ix.com/company/bioporto/news/private-placement-40-438-426-221300587</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/private-placement-40-438-426-221300587</guid>
<pubDate>Thu, 13 Nov 2025 22:13:00 GMT</pubDate>
<description>13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S Copenhagen, Denmark, 13 November 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), announces that the private placement of 40,438,426 new shares has been completed. The initiation of the private placement was announced in Announcement no. 24. Jens Due Olsen, Chair of the Board of BioPorto, commented: “We</description>
</item>
<item>
<title>BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement</title>
<link>https://6ix.com/company/bioporto/news/bioporto-executes-financing-strategy-bioporto-185000677</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-executes-financing-strategy-bioporto-185000677</guid>
<pubDate>Thu, 13 Nov 2025 18:50:00 GMT</pubDate>
<description>13 November 2025 Announcement no. 24 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR A PUBLIC OFFER OF THE SECURITIES DESCRIBED HEREIN NOR IS IT AN OFFER TO SELL OR ISSUE, OR A SOLICITATIO</description>
</item>
<item>
<title>Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs</title>
<link>https://6ix.com/company/bioporto/news/business-strategy-forward-strategic-direction-211000993</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/business-strategy-forward-strategic-direction-211000993</guid>
<pubDate>Tue, 04 Nov 2025 21:10:00 GMT</pubDate>
<description>November 4, 2025Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced a business strategy update, aspirations towards 2028 and funding needed to support the business until cash flow positive in the second half of 2027. CEO Carsten Buhl will present the Business Strategy Update on an investor webca</description>
</item>
<item>
<title>Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025</title>
<link>https://6ix.com/company/bioporto/news/pre-announcement-key-financial-results-210800826</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/pre-announcement-key-financial-results-210800826</guid>
<pubDate>Tue, 04 Nov 2025 21:08:00 GMT</pubDate>
<description>November 4, 2025 Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today pre-announced the key financial results for the third quarter of 2025 and revised guidance for 2025. Key Financial Results for Q3 2025 reflect Continued NGAL Sales Growth Revenue in the third quarter of 2025 totaled DKK 10.4 million, represent</description>
</item>
<item>
<title>Progress Update on BioPorto’s Adult Clinical Study</title>
<link>https://6ix.com/company/bioporto/news/progress-bioporto-adult-clinical-study-210700560</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/progress-bioporto-adult-clinical-study-210700560</guid>
<pubDate>Tue, 04 Nov 2025 21:07:00 GMT</pubDate>
<description>November 4, 2025Announcement no. 21 Progress Update on BioPorto’s Adult Clinical Study Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced an update on its ongoing adult clinical study in the US. At the end of October 2025, BioPorto successfully completed patient enrollment in its clinical cut-off study. The Company is in the process of collecting the study data, and this process is taking more time than initially ant</description>
</item>
<item>
<title>BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented</title>
<link>https://6ix.com/company/bioporto/news/bioporto-sponsors-conferences-pediatric-critical-081300328</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/bioporto-sponsors-conferences-pediatric-critical-081300328</guid>
<pubDate>Fri, 26 Sep 2025 08:13:00 GMT</pubDate>
<description>September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acute</description>
</item>
<item>
<title>US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker</title>
<link>https://6ix.com/company/bioporto/news/us-news-world-report-webinar-062600058</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/us-news-world-report-webinar-062600058</guid>
<pubDate>Thu, 11 Sep 2025 06:26:00 GMT</pubDate>
<description>September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run</description>
</item>
<item>
<title>Grant of Warrants</title>
<link>https://6ix.com/company/bioporto/news/grant-warrants-161500285</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/grant-warrants-161500285</guid>
<pubDate>Mon, 01 Sep 2025 16:15:00 GMT</pubDate>
<description>September 1, 2025 Announcement no. 20 Grant of Warrants Copenhagen, Denmark, September 1, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 5,000,000 warrants to a member of the Executive Management. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.28 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are</description>
</item>
<item>
<title>ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.</title>
<link>https://6ix.com/company/bioporto/news/pronephro-aki-ngal-early-detection-100600808</link>
<guid isPermaLink="true">https://6ix.com/company/bioporto/news/pronephro-aki-ngal-early-detection-100600808</guid>
<pubDate>Thu, 28 Aug 2025 10:06:00 GMT</pubDate>
<description>August 28, 2025News Release ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics is first major commercial step to significantly advance adoption of ProNephro AKI across US hospital institutions. COPENHAGEN, DENMARK and BOSTON, MA, USA, August 28 – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), today announced ProNephro AKI (NGAL), the Company’s te</description>
</item>
</channel>
</rss>